These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 11967803

  • 1. Ongoing Clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction.
    McMurray J, Berry C.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):131-6. PubMed ID: 11967803
    [No Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin II receptor blockers in chronic heart failure--not as ELITE as expected!
    Farquharson CA, Struthers AD.
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):21-2. PubMed ID: 11967790
    [Abstract] [Full Text] [Related]

  • 4. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M, Lamas GA.
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [Abstract] [Full Text] [Related]

  • 5. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Nov; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 6. ACE inhibitors vs. angiotensin II receptor blockers in acute myocardial infarction and heart failure.
    Gold JA, Rahko PS.
    WMJ; 2004 Nov; 103(1):71-2. PubMed ID: 15101473
    [No Abstract] [Full Text] [Related]

  • 7. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 8. Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure.
    Hanon S, Vijayaraman P, Sonnenblick EH, Le Jemtel TH.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 16; 1(2):147-50. PubMed ID: 11967806
    [No Abstract] [Full Text] [Related]

  • 9. [Blockade of the renin-angiotensin system. ACE inhibitors, angiotensin II antagonists or both?].
    Karlsen FM, Kamper AL.
    Ugeskr Laeger; 2003 Oct 13; 165(42):4006-9. PubMed ID: 14610833
    [No Abstract] [Full Text] [Related]

  • 10. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Oct 13; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 11. [Converting enzyme inhibitors in acute myocardial infarct and heart failure].
    Arslanagić A, Raljević E.
    Med Arh; 1999 Oct 13; 53(1):29-31. PubMed ID: 10356928
    [Abstract] [Full Text] [Related]

  • 12. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 13; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 13. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P.
    J Hypertens; 2008 Jul 13; 26(7):1282-9. PubMed ID: 18550998
    [Abstract] [Full Text] [Related]

  • 14. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.
    Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM.
    Arch Intern Med; 2007 Oct 08; 167(18):1930-6. PubMed ID: 17923591
    [Abstract] [Full Text] [Related]

  • 15. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
    Dickstein K.
    Am Heart J; 2003 May 08; 145(5):754-7. PubMed ID: 12766730
    [No Abstract] [Full Text] [Related]

  • 16. Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Singh RK, Barker S.
    Curr Opin Investig Drugs; 2005 Mar 08; 6(3):269-74. PubMed ID: 15816503
    [Abstract] [Full Text] [Related]

  • 17. A hard look at angiotensin receptor blockers in heart failure.
    Gring CN, Francis GS.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1841-6. PubMed ID: 15519017
    [Abstract] [Full Text] [Related]

  • 18. Cellular basis for therapeutic choices in heart failure.
    Opie LH.
    Circulation; 2004 Oct 26; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract] [Full Text] [Related]

  • 19. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 20. Are angiotensin II receptor antagonists indicated in chronic heart failure?
    Komajda M.
    Heart Fail Monit; 2002 Feb 21; 2(3):85-7. PubMed ID: 12634889
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.